PATENT CLAIM ANALYSIS

Application Number: 15901512
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-09
Patent Classification: ["514", "019300"]

Abstract:
Provided herein are compositions comprising interleukin-22 binding protein (IL-22BP) fusion proteins, and methods of using such fusions to inhibit IL-22 and signaling downstream thereof, as well as for the treatment and/or prevention of disease (e.g., cancer).

Claim (Index 9):
The composition of  claim 3 , wherein the IL-22BP polypeptide and the modifier peptide or polypeptide are connected directly, by a peptide linker, or by a non-peptide linker.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 88.0
- Lexical Diversity: 1.18919
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15801867', '15217790', '15454662', '14214161', '13404241']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6992995075934658
- 35 USC 102 Novelty (BERT): 0.5033951403862079
- Combined Prediction Score: 0.67970907087274
- Mean Citation Score: 188.020444
- Max Citation Score: 190.00902
- Similarity Product: 123.16263028703212

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test